Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C28H35ClN4O.2ClH |
| Molecular Weight | 551.979 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.ClC1=CC2=C(CCC3=CC=CC=C3N2CCCN4CCC5(CC4)N6CCCCC6NC5=O)C=C1
InChI
InChIKey=CVCDAZZJQWLXHM-UHFFFAOYSA-N
InChI=1S/C28H35ClN4O.2ClH/c29-23-12-11-22-10-9-21-6-1-2-7-24(21)32(25(22)20-23)16-5-15-31-18-13-28(14-19-31)27(34)30-26-8-3-4-17-33(26)28;;/h1-2,6-7,11-12,20,26H,3-5,8-10,13-19H2,(H,30,34);2*1H
| Molecular Formula | C28H35ClN4O |
| Molecular Weight | 479.057 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/10072664Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/8690306
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10072664
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/8690306
Mosapramine (Cremin) is used to treat chronic schizophrenia in Japan. It is a potent dopamine antagonist with high affinity to the dopamine receptor subtypes 2, 3 and 4, and with moderate affinity for the 5-HT2 receptors
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL219 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8690306 |
|||
Target ID: CHEMBL234 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8690306 |
|||
Target ID: CHEMBL217 Sources: Mosapramine showed the highest affinities for these receptor subtypes among the antipsychotics tested |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 21:12:15 GMT 2025
by
admin
on
Mon Mar 31 21:12:15 GMT 2025
|
| Record UNII |
6M1W6HZL1X
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
135775
Created by
admin on Mon Mar 31 21:12:15 GMT 2025 , Edited by admin on Mon Mar 31 21:12:15 GMT 2025
|
PRIMARY | |||
|
SUB03337MIG
Created by
admin on Mon Mar 31 21:12:15 GMT 2025 , Edited by admin on Mon Mar 31 21:12:15 GMT 2025
|
PRIMARY | |||
|
C046384
Created by
admin on Mon Mar 31 21:12:15 GMT 2025 , Edited by admin on Mon Mar 31 21:12:15 GMT 2025
|
PRIMARY | |||
|
98043-60-8
Created by
admin on Mon Mar 31 21:12:15 GMT 2025 , Edited by admin on Mon Mar 31 21:12:15 GMT 2025
|
PRIMARY | |||
|
6M1W6HZL1X
Created by
admin on Mon Mar 31 21:12:15 GMT 2025 , Edited by admin on Mon Mar 31 21:12:15 GMT 2025
|
PRIMARY | |||
|
DTXSID30913492
Created by
admin on Mon Mar 31 21:12:15 GMT 2025 , Edited by admin on Mon Mar 31 21:12:15 GMT 2025
|
PRIMARY | |||
|
m7633
Created by
admin on Mon Mar 31 21:12:15 GMT 2025 , Edited by admin on Mon Mar 31 21:12:15 GMT 2025
|
PRIMARY | Merck Index | ||
|
656595
Created by
admin on Mon Mar 31 21:12:15 GMT 2025 , Edited by admin on Mon Mar 31 21:12:15 GMT 2025
|
PRIMARY | |||
|
CHEMBL2106650
Created by
admin on Mon Mar 31 21:12:15 GMT 2025 , Edited by admin on Mon Mar 31 21:12:15 GMT 2025
|
PRIMARY | |||
|
100000085703
Created by
admin on Mon Mar 31 21:12:15 GMT 2025 , Edited by admin on Mon Mar 31 21:12:15 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |